|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||156.74 - 159.19|
|52-week range||95.21 - 172.74|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||0.52|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple biomarkers in primary biliary cholangitis.
Merck (MRK) files a lawsuit against claiming that the federal government is violating the Constitution by forcing drugmakers to negotiate prices at below market rates.
Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.
Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.
Novo Nordisk shares have been hot in 2023, up more than 19% and outperforming the S&P 500. Can momentum sustain?
Novo Nordisk (NYSE: NVO) had yet another good session on the stock market Tuesday. The company said it has accumulated just under 1.25 million shares of its B Class of stock, at a total transaction value of 1.42 billion krone ($204 million).
Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's
Updated data from a mid-stage study showed that Moderna (MRNA)/Merck's personalized cancer vaccine combined with Keytruda reduces the skin cancer's spreading by 65% in melanoma patients.
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.
At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.
VIPS, KOF and NVO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 5, 2023.
Here is how Novo Nordisk (NVO) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.
Novo Nordisk's (NYSE: NVO) semaglutide is everywhere in the news, and for good reason. Thanks to its ability to help people lose weight and control their diabetes symptoms, its moneymaking potential is practically off the charts. At the moment, semaglutide is indicated to treat obesity and type 2 diabetes, and it's available in a few different formulations, which vary depending on the dosage and whether it's administered via a weekly injection or a once-per-day pill.
NEM, KMT, VIPS, NVO and BAMXF have been added to the Zacks Rank #1 (Strong Buy) List on June 5, 2023.
It wasn't because so many patients were newly diagnosed with type 2 diabetes. Instead, Ozempic gained widespread popularity for helping people lose weight. A sibling product, Wegovy, a higher-dose version of the active ingredient in Ozempic that is actually approved for weight loss, has flown off pharmacies' shelves as well.
The Danish company said it had entered into exclusive negotiations with Bio Jag, Biocorp's main shareholder, for the purchase of its over 45% stake in the French company at a price of 35.0 euros ($37.44) per share in cash. The price represents a premium of 19.5% over Biocorp's closing market price on June 2 and the transaction values Biocorp at about 154 million euros, the companies said. Certain minority shareholders, representing 19.0% of the share capital of Biocorp, will also transfer shares to Novo Nordisk and the transaction will be followed by a squeeze-out procedure.
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.
These stocks have moved in opposite directions lately, but both could deliver solid returns to patient investors.
A highly lucrative weight-loss market could be the growth opportunity Pfizer needs to make the stock a better buy.
The company's sales doubled last quarter, prompting it to upgrade its guidance.
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
Two that come to mind are Danish pharmaceutical company Novo Nordisk (NYSE: NVO) and U.S.-based integrated healthcare benefits company UnitedHealth Group (NYSE: UNH). The companies have their own tailwinds as well, with Novo Nordisk building revenue off its weight-loss franchise and UnitedHealth Group finding its foray into Medicare Advantage to be lucrative. Novo Nordisk's shares are up more than 19%.